Pharmacokinetic and safety profile of tofacitinib in children with polyarticular course juvenile idiopathic arthritis: results of a phase 1, open-label, multicenter study

BACKGROUND: Juvenile idiopathic arthritis (JIA) is the most common pediatric rheumatic disease and a leading cause of childhood disability. The objective of this study was to characterize the PK, safety, and taste acceptability of tofacitinib in patients with JIA. METHODS: This Phase 1, open-label,...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Pediatr Rheumatol Online J
Egile Nagusiak: Ruperto, Nicolino, Brunner, Hermine I., Zuber, Zbigniew, Tzaribachev, Nikolay, Kingsbury, Daniel J., Foeldvari, Ivan, Horneff, Gerd, Smolewska, Elzbieta, Vehe, Richard K., Hazra, Anasuya, Wang, Rong, Mebus, Charles A., Alvey, Christine, Lamba, Manisha, Krishnaswami, Sriram, Stock, Thomas C., Wang, Min, Suehiro, Ricardo, Martini, Alberto, Lovell, Daniel J.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: BioMed Central 2017
Gaiak:
Research Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC5745974/
https://ncbi.nlm.nih.gov/pubmed/29282090
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12969-017-0212-y
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak